Suppr超能文献

一项前瞻性、随机、对照临床研究,旨在评估在辅助生殖技术(体外受精)项目中接受多卵泡卵巢刺激的女性皮下注射与肌肉注射Merional(hMG - IBSA)的耐受性和临床疗效。

A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF).

作者信息

Alviggi Carlo, Revelli Alberto, Anserini Paola, Ranieri Antonio, Fedele Luigi, Strina Ida, Massobrio Marco, Ragni Nicola, De Placido Giuseppe

机构信息

Department of Obstetrica/Gynecological Sciences and Reproductive Medicine, Federico II University, Napoli, Italy.

出版信息

Reprod Biol Endocrinol. 2007 Dec 4;5:45. doi: 10.1186/1477-7827-5-45.

Abstract

BACKGROUND

Multifollicular ovarian stimulation (MOS) is widely used in IVF and the compliance to treatment is deeply influenced by the tolerability of the medication(s) used and by the ease of self-administration. This prospective, controlled, randomised, parallel group open label, multicenter, phase III, equivalence study has been aimed to compare the clinical effectiveness (in terms of oocytes obtained) and tolerability of subcutaneous (s.c.) self-administered versus classical intramuscular (i.m.) injections of Merional, a new highly-purified hMG preparation.

METHODS

A total of 168 normogonadotropic women undergoing IVF were enrolled. Among them, 160 achieved pituitary suppression with a GnRH-agonist long protocol and were randomised to MOS treatment with Merional s.c. or i.m. They started MOS with a standard hMG dose between 150-300 IU, depending upon patient's age, and underwent a standard IVF procedure.

RESULTS

No statistically significant difference in the mean number of collected oocytes (primary endpoint) was observed between the two study subgroups (7.46, SD 4.24 vs. 7.86, SD 4.28 in the s.c. and i.m. subgroups, respectively). As concerns the secondary outcomes, both the pregnancy and the clinical pregnancy rates were comparable between subgroups. The incidence of adverse events was similar in the two groups (2.4% vs. 3.7%, respectively). Pain at injection site was reported only the i.m. group (13.9% of patients).

CONCLUSION

Merional may be used by s.c. injections in IVF with an effectiveness in terms of retrieved oocytes that is equivalent to the one obtained with i.m administration and with a better local tolerability. With the limitations due to the sample size af this study, s.c. and i.m. administration routes seem to have the same overall safety.

摘要

背景

多卵泡卵巢刺激(MOS)在体外受精(IVF)中被广泛应用,治疗的依从性深受所用药物的耐受性以及自我给药的便捷程度影响。这项前瞻性、对照、随机、平行组开放标签、多中心、III期等效性研究旨在比较皮下(s.c.)自我注射与传统肌肉注射新型高纯度人绝经期促性腺激素(hMG)制剂Merional的临床有效性(以获得的卵母细胞数量衡量)和耐受性。

方法

共纳入168名接受IVF的正常促性腺激素水平女性。其中,160名采用促性腺激素释放激素(GnRH)激动剂长方案实现垂体抑制,并被随机分配接受Merional皮下或肌肉注射进行MOS治疗。她们根据患者年龄,以150 - 300国际单位(IU)的标准hMG剂量开始MOS治疗,并接受标准IVF程序。

结果

两个研究亚组之间在收集的卵母细胞平均数量(主要终点)上未观察到统计学显著差异(皮下和肌肉注射亚组分别为7.46,标准差4.24和7.86,标准差4.28)。关于次要结局,亚组之间的妊娠率和临床妊娠率相当。两组不良事件发生率相似(分别为2.4%和3.7%)。仅在肌肉注射组报告了注射部位疼痛(13.9%的患者)。

结论

在IVF中,Merional可通过皮下注射使用,在获取卵母细胞方面的有效性等同于肌肉注射,且局部耐受性更好。鉴于本研究样本量的局限性,皮下和肌肉注射途径似乎具有相同的总体安全性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验